vs

Side-by-side financial comparison of IONIS PHARMACEUTICALS INC (IONS) and Navios Maritime Partners L.P. (NMM). Click either name above to swap in a different company.

Navios Maritime Partners L.P. is the larger business by last-quarter revenue ($327.6M vs $203.3M, roughly 1.6× IONIS PHARMACEUTICALS INC). Navios Maritime Partners L.P. runs the higher net margin — 21.4% vs -112.8%, a 134.2% gap on every dollar of revenue. On growth, Navios Maritime Partners L.P. posted the faster year-over-year revenue change (-4.3% vs -10.3%).

Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015.

Navios Maritime Holdings Inc. is a multinational, vertically integrated seaborne shipping and logistics company focused on the transport and transshipment of drybulk commodities including iron ore, coal and grain.

IONS vs NMM — Head-to-Head

Bigger by revenue
NMM
NMM
1.6× larger
NMM
$327.6M
$203.3M
IONS
Growing faster (revenue YoY)
NMM
NMM
+6.0% gap
NMM
-4.3%
-10.3%
IONS
Higher net margin
NMM
NMM
134.2% more per $
NMM
21.4%
-112.8%
IONS

Income Statement — Q4 FY2025 vs Q2 FY2025

Metric
IONS
IONS
NMM
NMM
Revenue
$203.3M
$327.6M
Net Profit
$-229.4M
$69.9M
Gross Margin
96.1%
90.5%
Operating Margin
-105.5%
Net Margin
-112.8%
21.4%
Revenue YoY
-10.3%
-4.3%
Net Profit YoY
-119.8%
-31.1%
EPS (diluted)
$-1.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IONS
IONS
NMM
NMM
Q4 25
$203.3M
Q3 25
$156.7M
Q2 25
$452.0M
$327.6M
Q1 25
$131.6M
Q4 24
$226.6M
Q3 24
$133.8M
Q2 24
$225.3M
$342.2M
Q1 24
$119.5M
Net Profit
IONS
IONS
NMM
NMM
Q4 25
$-229.4M
Q3 25
$-128.6M
Q2 25
$123.6M
$69.9M
Q1 25
$-146.9M
Q4 24
$-104.3M
Q3 24
$-140.5M
Q2 24
$-66.3M
$101.5M
Q1 24
$-142.8M
Gross Margin
IONS
IONS
NMM
NMM
Q4 25
96.1%
Q3 25
98.5%
Q2 25
99.1%
90.5%
Q1 25
98.9%
Q4 24
98.3%
Q3 24
99.2%
Q2 24
98.2%
88.3%
Q1 24
98.2%
Operating Margin
IONS
IONS
NMM
NMM
Q4 25
-105.5%
Q3 25
-102.2%
Q2 25
30.9%
Q1 25
-111.6%
Q4 24
-48.9%
Q3 24
-111.1%
Q2 24
-29.3%
Q1 24
-125.1%
Net Margin
IONS
IONS
NMM
NMM
Q4 25
-112.8%
Q3 25
-82.1%
Q2 25
27.3%
21.4%
Q1 25
-111.6%
Q4 24
-46.1%
Q3 24
-105.0%
Q2 24
-29.4%
29.7%
Q1 24
-119.5%
EPS (diluted)
IONS
IONS
NMM
NMM
Q4 25
$-1.35
Q3 25
$-0.80
Q2 25
$0.70
Q1 25
$-0.93
Q4 24
$-0.66
Q3 24
$-0.95
Q2 24
$-0.45
Q1 24
$-0.98

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IONS
IONS
NMM
NMM
Cash + ST InvestmentsLiquidity on hand
$2.7B
$377.0M
Total DebtLower is stronger
$1.8B
$2.0B
Stockholders' EquityBook value
$489.1M
Total Assets
$3.5B
$5.9B
Debt / EquityLower = less leverage
3.71×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IONS
IONS
NMM
NMM
Q4 25
$2.7B
Q3 25
$2.2B
Q2 25
$2.3B
$377.0M
Q1 25
$2.1B
Q4 24
$2.3B
Q3 24
$2.5B
Q2 24
$2.1B
$272.0M
Q1 24
$2.2B
Total Debt
IONS
IONS
NMM
NMM
Q4 25
$1.8B
Q3 25
Q2 25
$2.0B
Q1 25
Q4 24
$1.3B
Q3 24
Q2 24
$1.4B
Q1 24
Stockholders' Equity
IONS
IONS
NMM
NMM
Q4 25
$489.1M
Q3 25
$618.0M
Q2 25
$631.7M
Q1 25
$475.7M
Q4 24
$588.4M
Q3 24
$662.5M
Q2 24
$263.7M
Q1 24
$296.5M
Total Assets
IONS
IONS
NMM
NMM
Q4 25
$3.5B
Q3 25
$3.0B
Q2 25
$3.0B
$5.9B
Q1 25
$2.8B
Q4 24
$3.0B
Q3 24
$3.1B
Q2 24
$2.7B
$5.3B
Q1 24
$2.8B
Debt / Equity
IONS
IONS
NMM
NMM
Q4 25
3.71×
Q3 25
Q2 25
Q1 25
Q4 24
2.13×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IONS
IONS
NMM
NMM
Operating Cash FlowLast quarter
$-137.7M
Free Cash FlowOCF − Capex
$-159.0M
FCF MarginFCF / Revenue
-78.2%
Capex IntensityCapex / Revenue
10.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-320.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IONS
IONS
NMM
NMM
Q4 25
$-137.7M
Q3 25
$-131.4M
Q2 25
$151.3M
Q1 25
$-150.8M
Q4 24
$-116.1M
Q3 24
$-115.0M
Q2 24
$-119.9M
Q1 24
$-149.9M
Free Cash Flow
IONS
IONS
NMM
NMM
Q4 25
$-159.0M
Q3 25
$-136.7M
Q2 25
$139.0M
Q1 25
$-163.4M
Q4 24
$-141.6M
Q3 24
$-124.0M
Q2 24
$-126.1M
Q1 24
$-154.4M
FCF Margin
IONS
IONS
NMM
NMM
Q4 25
-78.2%
Q3 25
-87.2%
Q2 25
30.8%
Q1 25
-124.1%
Q4 24
-62.5%
Q3 24
-92.7%
Q2 24
-56.0%
Q1 24
-129.2%
Capex Intensity
IONS
IONS
NMM
NMM
Q4 25
10.5%
Q3 25
3.4%
Q2 25
2.7%
Q1 25
9.6%
Q4 24
11.3%
Q3 24
6.8%
Q2 24
2.8%
Q1 24
3.8%
Cash Conversion
IONS
IONS
NMM
NMM
Q4 25
Q3 25
Q2 25
1.22×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IONS
IONS

Products$58.0M29%
Spinraza Royalties$54.0M27%
Collaborative Agreement Revenue$52.4M26%
Wainus Royalties$16.0M8%
Wainua Joint Development Revenue$9.6M5%
Other Commercial$7.6M4%
Other Royalties$5.7M3%

NMM
NMM

Segment breakdown not available.

Related Comparisons